- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03958591
Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification (ESTIMATOR)
Effects of Short-Term Intensive De-escalation Therapy on Long-term Regimen Simplification in Patients With Poorly Controlled Type 2 Diabetes-- a Multicenter, Open-labeled, Randomized Controlled Trial
Study Overview
Status
Conditions
Detailed Description
This is a multicenter, randomized, controlled, open-label, clinical superiority trial. The participants will be recruited from 19 centers in China. The enrolled participants will be randomly assigned into 3 groups, designated as Group A , B and C.
Group A (Intensive therapy group following up with intelligent equipment):Continuous subcutaneous insulin infusion (CSII) will be applied to the participants for 2 weeks and thereafter the combination therapy of basal insulin, metformin and vildagliptin for the next 10 weeks. The participants are followed up with intelligent equipment.
Group B (Intensive therapy group following up in traditional ways): CSII will be applied to the participants for 2 weeks and thereafter the combination therapy of basal insulin, metformin and vildagliptin for the next 10 weeks. The participants are followed up in traditional ways.
Group C (Traditionally upgrading group): The participants will be applied the combination therapy of basal insulin, vildagliptin and metformin for the entire 12 weeks.
Participants in both Group A, B and Group C will then receive combination therapy of metformin and vildagliptin, and be followed-up at the 16th, 20th, 24th, 28th, 32nd and 36th weeks. The doses of metformin and vildagliptin are set as 1.0~2.0g/d and 100mg/d, respectively. If the participants cannot tolerate metformin, then acarbose (50-100mg tid) or SGLT2 inhibitor can be instead used. If glucose is not well controlled, sulfonylureas or glinides can be added as a rescue treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Lijuan Xu, Dr
- Phone Number: 8144 020-87755766
- Email: xulijuan@mail.sysu.edu.cn
Study Contact Backup
- Name: Lijuan Xu, Dr
- Phone Number: 8144 020-87755766
- Email: jin9998@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Department of endocrinology, FAH-SYSU
-
Contact:
- Lijuan Xu, Dr
- Phone Number: 8144 020-87755766
- Email: xulijuan@mail.sysu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes diagnosed according to WHO criteria (1999); With a duration of 1~10 years;
- With two or more oral hypoglycemic drug used for at least 3 months, including at least one insulin secretagogue in half-max dosage (eg. Glibenclamide 7.5mg/d, gliclazide 60mg/d, glimepiride 3mg/d, glipizide 10mg/d, repaglinide 6mg/d, nateglinide 360mg/d and DPP-4 inhibitor with regular doses);
- HbA1c of 7.5 to 13% and fasting C-peptide >0.4 nmol/L;
- Age of 18 to 70 years;
- BMI of 20 to 35 kg/m²;
Capable of and willing to follow doctors' instructions to:
Self-monitor blood glucose according to the protocol;
- Follow the protocol and have regular visits as required; ③ Record and maintain the research diary, as required by the protocol; ④ Keep contact with the investigators and receive phone calls during the study.
Exclusion Criteria:
- Type 1 diabetes or specific types of diabetes;
- Those who have received premixed insulin therapy and/or basal - meal insulin and/or basal insulin-oral hypoglycemic agents treatment accumulation for 7 days or more, and those who have received CSII therapy in the last one year, and those who have received GLP-1 analogue within 3 months before screening;
- Those who have acute diabetic complications (diabetic ketoacidosis, hyperosmotic hyperglycemia coma or lactic acidosis);
- Those who have severe diabetic microvascular complications (proliferative retinopathy, clinical proteinuria, and glomerular filtration rate less than 45 ml/min, uncontrolled diabetic neuropathy and obvious diabetic autonomic neuropathy);
- Those with ALT >2.5 times of the upper limit of normal (ULN), bilirubin > 1.5 times of ULN;
- Those with known macrovascular disease: Patients with acute cerebrovascular accident, acute coronary syndrome, unstable angina, peripheral artery disease who have received vascular intervention or amputation in the 12 months before enrollment; Or chronic cardiac dysfunction with cardiac function grade III or above;
- Those with poor blood pressure control (systolic blood pressure≥160mmHg and/or sitting diastolic blood pressure ≥110mmHg) and inability to control under 160/110mmhg within 1 week;
- Serious systemic disease or malignant tumor, chronic diarrhea, etc;
- Those with drugs that may affect blood glucose for a cumulative time of more than 1 week within 12 weeks, such as oral/venous glucocorticoid, growth hormone, estrogen/ progesterone, high-dose diuretics, antipsychotic drugs. However, low-dose diuretics for antihypertensive purposes (HCTZ < 25mg/d, indapamide < 1.5mg/d) and physiologic dose of thyroid hormone for replacement therapy are not included;
- Any factors that may affect the participation of the subject in the study or the evaluation of the results;
- Pregnancy or planned pregnancy, lactation subjects.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive-de-escalation group with intelligent management
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied.
Then the oral hypoglycemic therapies will be prescribed.
Wearable devices and smart apps will be used to manage and follow-up patients.
|
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
Other Names:
|
Experimental: Intensive-de-escalation group without intelligent management
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied.
Then the oral hypoglycemic therapies will be prescribed.
Traditional ways such as telephone contact will be used to follow-up patients.
|
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
Other Names:
|
Active Comparator: Traditionally upgrading group
The combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks and thereafter the oral hypoglycemic therapies will be applied.
Traditional ways will be used to follow-up patients.
|
The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks.
Traditional ways will be used for follow up.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportions of treatment simplification
Time Frame: 24 weeks after the insulin treatment
|
the proportions of patients who can maintain glycemic targets (HbA1c<7%) with only combination of oral hypoglycemic agents
|
24 weeks after the insulin treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yanbing Li, Dr, FAH-SYSU
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018YFC1314103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes type2
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Johns Hopkins UniversityBeth Israel Deaconess Medical CenterActive, not recruitingHypertension | Diabetes Mellitus, Type 2 | Diabetes | Diabetes type2 | Type 2 Diabetes | Type2 Diabetes | Type II Diabetes | High Blood PressureUnited States
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
University of ChicagoCompleted
-
Michigan State UniversityUniversity of Michigan; Claremont Graduate UniversityUnknown
-
University of AlbertaSherwood Park Strathcona County Primary Care Network, AlbertaCompleted
-
Brittany L SmallsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
LMC Diabetes & Endocrinology Ltd.Merck Sharp & Dohme LLC; Syreon CorporationWithdrawnType2 Diabetes
Clinical Trials on CSII and thereafter combination therapy, followed up with wearable devices
-
LI XIN-XIANGNot yet recruitingAdvanced Rectal Cancer | Distal MetastasisChina
-
West Japan Thoracic Oncology GroupCompleted
-
Imperial College LondonNot yet recruiting